Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance - Gilead Sciences (NASDAQ:GILD)

Gilead rises after earnings beat driven by HIV drug sales

The company expects Yeztugo to contribute $800 million in revenue in 2026....

Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug

Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Inc. (NASDAQ:GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance. Here's a look at the key figures from the quarter.  GILD stock is moving. Watch the price action here. The Details: Gilead reported quarterly earnings of $1.86 per share, which beat the consensus estimate of $1.81, according to data from Benzinga Pro. Quarterly revenue came…

Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target - Pharmaceutical Technology

Analysts said that Yeztugo’s forecast, which would represent 433% year-over-year growth, is achievable.